---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003344"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:14:46.092811+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April

## Summary
- Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.
- Cash $16.0M as of Dec 31, 2024 (down from $22.4M); expected to fund operations into Q3 2025.
- DA-1726: Top-line data from additional MAD Part 2 cohorts expected April 2025; proof-of-concept study planned Q4 2025.
- DA-1241: Phase 2a in MASH met primary endpoint (ALT reduction); full data at medical meeting 2025; FDA end-of-Phase 2 meeting H1 2025.

## SEC filing metadata
- accession: 0001558370-25-003344
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/0001558370-25-003344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003344
- JSON: https://secwatch.observer/filing/0001558370-25-003344.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.